Autoimmune encephalitis relapse risk after immunotherapy is associated with a combination of immunological, neuronal injury, imaging, and clinical markers. Evidence from leading centers shows that some tests carry stronger predictive value than others, and that patterns vary by antibody type and care context.
Biological markers
CSF antibody persistence is a consistent predictor in N-methyl-D-aspartate receptor encephalitis. Josep Dalmau University of Pennsylvania described that persistent cerebrospinal fluid antibodies and high CSF titers correlate more closely with clinical relapse than serum titers and that intrathecal antibody production often signals ongoing central nervous system autoimmunity. Oligoclonal bands and evidence of intrathecal IgG synthesis reported by Harald Prüss Charité — Universitätsmedizin Berlin further indicate sustained central immune activation that can precede relapse. Measures of neuronal damage such as neurofilament light chain in cerebrospinal fluid or serum have been linked by Henrik Zetterberg University of Gothenburg to worse recovery and may identify patients at risk of recurrent or progressive disease though thresholds and timing remain under study.
Clinical and contextual factors
Antibody specificity and tumor association matter. Maarten J. Titulaer Erasmus Medical Center has shown that paraneoplastic forms and certain antibody types carry different relapse probabilities; removal of an underlying tumor and prompt aggressive immunotherapy reduce recurrence risk. Work by Sarosh Irani University of Oxford and Michael Vincent University of Oxford indicates that LGI1 and CASPR2 syndromes often follow distinct relapse patterns compared with anti-NMDAR disease, affecting prognosis and monitoring strategy. Electrophysiological and imaging findings such as persistent epileptiform activity on EEG or hippocampal changes on MRI also increase concern for relapse when they persist after initial treatment.
Understanding these biomarkers is clinically relevant because relapse can lead to cumulative cognitive impairment, seizure burden, and social disruption. Access to serial CSF testing, high-sensitivity antibody assays, and tumor screening is uneven across regions, producing territorial and cultural disparities in relapse prevention and long-term outcomes. Integrating antibody dynamics, markers of neuronal injury, imaging and EEG surveillance, and attention to tumor status offers the best evidence-based approach to stratify relapse risk and guide maintenance immunotherapy while recognizing evolving evidence and local resource limits.